Kloss et al., then, thought to combine dnTGF-βRII with a PSMA-specific CAR to boost T cell infiltration, persistence, and efficacy, offering a promising therapeutic advance for prostate cancer treatment [124]. Here, FOLH1 is linked to prostate cancer.